GlassScriptPhysician profile
Lane M Knight
NPI 1235730102
$9,016.09
in general payments reported to CMS, 2019-2025
54 companies · $2,806 in 2025
The $2,806 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,235 · 2023: $2,368 · 2024: $2,608 · 2025: $2,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,680 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,679.98 |
| Education | $101.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,512.73 | 2022-2025 | |
| Pfizer INC. | $642.02 | 2022-2025 | |
| Ucb, INC. | $565.92 | 2022-2025 | Rystiggo, Briviact, Nayzilam |
| Emd Serono, INC. | $443.31 | 2022-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $384.01 | 2022-2025 | Ultomiris, Koselugo, Soliris |
| Lundbeck LLC | $366.54 | 2022-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $358.23 | 2022-2025 | Kisunla, Emgality, Amyvid |
| Novartis Pharmaceuticals Corporation | $311.72 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $288.34 | 2022-2025 | Rytary, Crexont |
| Neurocrine Biosciences, INC. | $249.01 | 2023-2025 | Ingrezza, Ongentys |
| Biogen, INC. | $236.86 | 2022-2025 | Skyclarys, Vumerity, Tysabri |
| Genzyme Corporation | $234.22 | 2023-2025 | |
| Argenx US, INC. | $227.35 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Tg Therapeutics, INC. | $210.62 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $206.73 | 2023-2025 | Rexulti, Nuedexta |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $198.33 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $192.43 | 2022-2025 | |
| Sk Life Science, INC. | $190.31 | 2022-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $159.69 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Kyowa Kirin, INC. | $143.26 | 2022-2024 | Nourianz |
| Jazz Pharmaceuticals INC. | $138.17 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.99 | 2023-2025 | Hyqvia, Gammagard |
| Sumitomo Pharma America, INC. | $116.82 | 2023-2024 | Aptiom |
| Medtronic, INC. | $111.82 | 2022-2023 | Graftonand Grafton Plusdemineralized Bone Matrix (Dbm), Atlantis Anterior Cervical Plate System |
| Celgene Corporation | $97.48 | 2022-2025 | Zeposia |
| Mdd US Operations, LLC | $95.41 | 2023-2024 | Gocovri, Gocovri |
| Mallinckrodt Hospital Products INC. | $83.10 | 2022-2025 | Acthar |
| Tanabe Pharma America, INC. | $73.45 | 2024-2025 | Radicava |
| Merz Pharmaceuticals, LLC | $68.75 | 2025 | Xeomin, Ampyra, Inbrija |
| Supernus Pharmaceuticals, INC. | $68.16 | 2025 | Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $67.48 | 2022 | |
| Axsome Therapeutics, INC. | $61.42 | 2023-2024 | Sunosi |
| Impel Pharmaceuticals LLC | $60.65 | 2025 | Trudhesa |
| Acadia Pharmaceuticals INC | $57.71 | 2025 | Nuplazid |
| Averitas Pharma INC. | $51.63 | 2025 | Qutenza |
| Mylan Specialty L.P. | $50.74 | 2023-2024 | Glatiramer Acetate |
| Xeris Pharmaceuticals, INC. | $49.27 | 2023-2025 | Keveyis |
| Amgen INC. | $47.51 | 2023 | Aimovig |
| Azurity Pharmaceuticals, INC. | $46.61 | 2023 | Horizant |
| Impel Pharmaceuticals INC. | $43.97 | 2023 | Trudhesa |
| Neurelis, INC. | $40.39 | 2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $39.60 | 2024 | |
| Janssen Pharmaceuticals, INC | $35.26 | 2022 | |
| Life Molecular Imaging LTD | $32.77 | 2025 | Neuraceq |
| Sunovion Pharmaceuticals INC. | $32.08 | 2022 | |
| Vanda Pharmaceuticals INC. | $28.67 | 2025 | Ponvory |
| Novo Nordisk INC | $25.05 | 2024 | Wegovy |
| Banner Life Sciences, LLC | $24.03 | 2022 | |
| Cycle Pharmaceuticals INC | $23.24 | 2025 | Tascenso Odt, Bafiertam |
| Scilex Pharmaceuticals INC. | $22.88 | 2024 | |
| Acorda Therapeutics, INC | $22.74 | 2023 | Inbrija, Ampyra |
| Alnylam Pharmaceuticals INC. | $21.70 | 2023 | Onpattro |
| Ani Pharmaceuticals, INC. | $19.43 | 2025 | Purified Cortrophin Gel |
| Collegium Pharmaceutical, INC. | $14.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lane Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.